Development and Validation of a Capillary Zone Electrophoresis Method for the Determination of Lacosamide in Pharmaceutical Dosage Forms Using Box–Behnken Experimental Design
Clicks: 5
ID: 323762
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
1.2
/100
5 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #305 of 358 articles by views in journal of aoac international
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 358 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Lacosamide (LAC) is a third-generation antiseizure medication requiring reliable analytical methods for pharmaceutical quality control. No capillary electrophoresis (CE) method has been reported for its determination in dosage forms, and existing HPLC methods often involve high solvent consumption and limited sensitivity. Objective To develop and validate a stability-indicating capillary zone electrophoresis method with diode array detection (CZE-DAD) for LAC determination in Lamide® tablets, optimized using a Box–Behnken design (BBD). Methods Separation was performed by using a bare fused-silica capillary (40 cm effective length, 75 µm i.d.) with 5.7 mM sodium acetate buffer (pH 4.0) at ∼23 kV and peaks were detected at 210 nm. Metoprolol succinate served as the internal standard. ICH Q2(R1) guideline is followed for validation. Stability was assessed under five ICH stress conditions, and in vitro dissolution was profiled in gastric (0.1 N HCl, pH 1.2) and intestinal (PBS, pH 6.8) media. Results The method demonstrated excellent linearity (r² = 0.9992) over 1.25 × 10⁻⁶ to 7.99 × 10⁻⁵ M, with LOD/LOQ of 0.034/0.102 µg/mL. Precision (%RSD) was <2.0%, and accuracy ranged from 99.61 to 101.81%. Mean LAC content in tablets was 98.21 ± 1.13% of the labelled amount. Forced degradation studies confirmed the stability-indicating capability of the method. In gastric medium, ≥95% release was achieved by 60–120 min; in intestinal medium, ≥95% was attained between 1 and 2 h. Conclusions The first CZE-DAD method for determination of LAC in pharmaceutical tablets was successfully validated. It offers 2.5–3.5-fold superior sensitivity and higher separation efficiency (N > 12,000) compared to reported HPLC methods. Minimal solvent consumption aligns with green analytical chemistry principles, making this method well-suited for routine quality control. Highlights First CE method reported for the determination of LAC in dosage forms; BBD-optimized with metoprolol succinate as internal standard; superior LOD (0.034 µg/mL); stability-indicating under five ICH stress conditions; biorelevant dissolution profiling.
| Reference Key |
openalex_W7172511428
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Kadri Güleç, Dilek Doğrukol‐Ak |
| Journal | journal of aoac international |
| Year | 2026 |
| DOI |
10.1093/jaoacint/qsag074
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.